Table 1.

cGVHD Risk Factors

	Patient	Donor/Graft	Transplant
Increased cGVHD risk	Older age Malignancy	Female donor to male patient Mismatched Unrelated Peripheral Blood Stem Cells Donor Lymphocyte Infusions Older age	Acute GVHD Total Body Irradiation in preparative regimen
Possible increased cGVHD risk	CMV positive CMV reactivation	CD 34+ cell dose
Decreased cGVHD risk	Younger age	Cord blood	Anti-thyroglobulin in preparative regimen Campath-1H in preparative regimen
Possible decreased cGVHD risk			Methotrexate and cyclosporine prophylaxis